loading page

ORAL MERCAPTOPURINE ADHERENCE IN PEDIATRIC ALL: A SURVEY STUDY FROM THE DFCI ALL CONSORTIUM
  • +7
  • Justine Kahn,
  • Maneka Puligandla,
  • Kristen Stevenson,
  • Peter Cole,
  • Jennifer Welch,
  • Melissa Beauchemin,
  • Elizabeth Gage-Bouchard,
  • Lewis Silverman,
  • Kara Kelly,
  • Kira Bona
Justine Kahn
Columbia University Medical Center
Author Profile
Maneka Puligandla
Dana Farber Cancer Institute
Author Profile
Kristen Stevenson
Dana-Farber Cancer Institute
Author Profile
Peter Cole
Rutgers The State University of New Jersey
Author Profile
Jennifer Welch
Hasbro Children's Hospital
Author Profile
Melissa Beauchemin
Columbia University Medical Centre
Author Profile
Elizabeth Gage-Bouchard
Roswell Park Comprehensive Cancer Center
Author Profile
Lewis Silverman
Dana Farber Cancer Institute
Author Profile
Kara Kelly
Roswell Park Comprehensive Cancer Center
Author Profile
Kira Bona
Dana-Farber Cancer Institute
Author Profile

Abstract

Poor adherence to 6-mercaptopurine during acute lymphoblastic leukemia (ALL) therapy increases relapse risk. Clinically-significant non-adherence has been documented in up to 30% of children treated for ALL on Children’s Oncology Group trials. Whether non-adherence rates vary across regimens with different chemotherapy schedules and modes of administration is not known. In a cross-sectional survey study of N= 61 children treated on, or as per Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 11-001, 25% (95% CI 14 – 37%) of respondents self-reported non-adherence to 6MP, suggesting that the frequency of non-adherence may be similar across different Consortia regimens.